Literature DB >> 1350908

Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease.

S Furukawa1, K Imai, T Matsubara, K Yone, A Yachi, K Okumura, K Yabuta.   

Abstract

OBJECTIVE: We investigated whether levels of intercellular adhesion molecule 1 (ICAM-1) antigen shed into the circulation increase during acute Kawasaki disease (KD). We also compared ICAM-1 levels in acute KD with those in anaphylactoid purpura (AP) and in measles.
METHODS: Serum ICAM-1 levels were measured by a double-determinant immunoassay using 2 monoclonal antibodies in the FAST (Falcon assay screening test) system. Serum levels of tumor necrosis factor alpha (TNF alpha) were measured by a specific and sensitive sandwich enzyme immunoassay.
RESULTS: Patients with KD, but not those with AP or measles, had increased levels of shed ICAM-1 antigen in serum samples obtained during acute stages. Moreover, during the acute stage, KD patients with coronary artery lesions (CAL) had still higher levels of shed ICAM-1 than did those without CAL. We found a positive correlation between serum levels of shed ICAM-1 and levels of TNF alpha during acute KD.
CONCLUSION: Our findings suggest that the serum ICAM-1 level is an important immunologic parameter for determining the severity of vascular damage during acute KD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350908     DOI: 10.1002/art.1780350611

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

1.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1.

Authors:  S F Penc; B Pomahac; E Eriksson; M Detmar; R L Gallo
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 3.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

Review 4.  Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases.

Authors:  P P Sfikakis; G C Tsokos
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

5.  Circulating adhesion molecules ICAM-1, E-selectin, and von Willebrand factor in Henoch-Schönlein purpura.

Authors:  O Söylemezoglu; N Sultan; T Gursel; N Buyan; E Hasanoglu
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

6.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.

Authors:  Haruyuki Makata; Takashi Ichiyama; Ryutaro Uchi; Tsuyoshi Takekawa; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

7.  Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus.

Authors:  N Tulek; O Aydintug; K Ozoran; H Tutkak; N Duzgun; M Duman; G Tokgoz
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

8.  Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease.

Authors:  M C Nash; V Shah; M J Dillon
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

9.  Circulating intercellular adhesion molecule 1 in rheumatoid arthritis--relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy.

Authors:  A Kuryliszyn-Moskal; K Bernacka; P A Klimiuk
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

10.  Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.

Authors:  A E Heufelder; R S Bahn
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.